On 18 December 2002, orphan designation (EU/3/02/124) was granted by the European Commission to Agence Générale des Equipements et Produits de Santé - Etablissement Pharmaceutique des Hôpitaux de Paris (AGEPS - EPHP), France, for 3,4 diaminopyridine phosphate for the treatment of Lambert-Eaton myasthenic syndrome.
The sponsorship was transferred to OPi, France, in April 2006. OPi changed its name to EUSA Pharma SAS in February 2008.
The sponsorship was subsequently transferred to BioMarin Europe Ltd, United Kingdom, in June 2010.
3,4 diaminopyridine phosphate has been authorised in the EU as Firdapse since 23 December 2009.
The sponsorship was transferred to BioMarin International Limited - Ireland, in June 2018.
|Disease / condition||
Treatment of Lambert-Eaton myasthenic syndrome
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.